ATE218139T1 - Xanthin-derivate - Google Patents

Xanthin-derivate

Info

Publication number
ATE218139T1
ATE218139T1 AT95909968T AT95909968T ATE218139T1 AT E218139 T1 ATE218139 T1 AT E218139T1 AT 95909968 T AT95909968 T AT 95909968T AT 95909968 T AT95909968 T AT 95909968T AT E218139 T1 ATE218139 T1 AT E218139T1
Authority
AT
Austria
Prior art keywords
lower alkyl
adenosine
different
same
represents hydrogen
Prior art date
Application number
AT95909968T
Other languages
English (en)
Inventor
Fumio Suzuki
Nobuaki Koike
Junichi Shimada
Joji Nakamura
Shizuo Shiozaki
Shigeto Kitamura
Shunji Ichikawa
Hiroshi Kase
Hiromi Nonaka
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Application granted granted Critical
Publication of ATE218139T1 publication Critical patent/ATE218139T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95909968T 1994-02-23 1995-02-23 Xanthin-derivate ATE218139T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2573694 1994-02-23
PCT/JP1995/000267 WO1995023148A1 (en) 1994-02-23 1995-02-23 Xanthine derivative

Publications (1)

Publication Number Publication Date
ATE218139T1 true ATE218139T1 (de) 2002-06-15

Family

ID=12174110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909968T ATE218139T1 (de) 1994-02-23 1995-02-23 Xanthin-derivate

Country Status (7)

Country Link
US (1) US5703085A (de)
EP (1) EP0698607B1 (de)
AT (1) ATE218139T1 (de)
AU (1) AU1823895A (de)
CA (1) CA2161011A1 (de)
DE (1) DE69526822T2 (de)
WO (1) WO1995023148A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
DE69834500T2 (de) * 1997-09-05 2007-05-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivative zur behandlung von hirnischämie
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6815446B1 (en) 1999-08-31 2004-11-09 Vanderbilt University Selective antagonists of A2B adenosine receptors
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
BR0306919A (pt) 2002-01-28 2004-11-09 Kyowa Hakko Kogyo Kk Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
KR20050026546A (ko) * 2002-07-29 2005-03-15 씨브이 쎄러퓨틱스, 인코포레이티드 Ａ2ａ 수용체 작용제를 이용한 심근 관류 조영
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20070078148A1 (en) * 2003-12-09 2007-04-05 Kyowa Hakko Kogyo Co., Ltd. Agents for preventing and/or treating higher brain dysfunctions
EP1738766A4 (de) * 2004-03-30 2010-05-12 Kyowa Hakko Kirin Co Ltd Mittel zur prävention und/oder behandlung von erkrankungen mit chronischen/knochenschmerzen
US7655636B2 (en) 2004-10-20 2010-02-02 Gilead Palo Alto, Inc. Use of A2A adenosine receptor agonists
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
BRPI0716174A2 (pt) * 2006-09-01 2013-09-24 Cv Therapeutics Inc mÉtodos e composiÇÕes para aumentar a tolerabilidade de paciente durante mÉtodos de imagem do miocÁrdio.
JP2011502101A (ja) * 2006-09-29 2011-01-20 ギリアード・パロ・アルト・インコーポレイテッド 肺疾患の病歴を有する患者における心筋画像化法
EP1939197A1 (de) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-Ethinylxanthinderivate als selektive Antagonisten des A2A-Rezeptors
MX2009006346A (es) * 2006-12-22 2010-03-03 Sanol Arznei Schwarz Gmbh Derivados de 8-etinilxantina como antagonistas de receptores de a2a selectivos.
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
EP2229388A4 (de) * 2008-01-11 2012-03-07 Glenmark Pharmaceuticals Sa Kondensierte pyrimidinderivate als trpv3-modulatoren
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
RU2011115815A (ru) * 2008-09-29 2012-11-10 Гайлид Сайэнсиз, Инк. (Us) Комбинации средства, регулирующего частоту сердечных сокращений и агониста а-2-альфа рецепторов для применения в способах мультидетекторной компьютерной томографии
US10184028B2 (en) 2016-01-11 2019-01-22 Industrial Technology Research Institute Method for preparing a polymer
US10287396B2 (en) 2016-01-11 2019-05-14 Industrial Technology Research Institute Polymer
US9994679B2 (en) * 2016-01-11 2018-06-12 Industrial Technology Research Institute Polymerization process of polyarylene sulfide
US10377705B2 (en) 2016-01-11 2019-08-13 Industrial Technology Research Institute Method for preparing polyarylene sulfide (PAS) monomer
WO2020216152A1 (en) * 2019-04-24 2020-10-29 Dongguan Hec New Drug R&D Co., Ltd. 8-substituted aryl vinyl xanthine derivatives and uses thereof
CN113248505B (zh) * 2021-06-09 2021-09-21 南京安杰新生物医药有限公司 伊曲茶碱去甲基杂质的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0559893B1 (de) * 1990-10-18 1999-02-03 Kyowa Hakko Kogyo Co., Ltd. Xanthinderivate
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
JP2928386B2 (ja) * 1992-07-08 1999-08-03 協和醗酵工業株式会社 うつ病治療剤
DE4325254A1 (de) * 1992-08-10 1994-02-17 Boehringer Ingelheim Kg Unsymmetrisch substituierte Xanthine
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
CA2112031A1 (en) * 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists

Also Published As

Publication number Publication date
DE69526822D1 (en) 2002-07-04
EP0698607A1 (de) 1996-02-28
EP0698607B1 (de) 2002-05-29
AU1823895A (en) 1995-09-11
WO1995023148A1 (en) 1995-08-31
EP0698607A4 (de) 1996-03-27
US5703085A (en) 1997-12-30
DE69526822T2 (de) 2003-01-23
CA2161011A1 (en) 1995-08-31

Similar Documents

Publication Publication Date Title
ATE218139T1 (de) Xanthin-derivate
ATE257156T1 (de) (1,2,4)triazolo(1,5-c)pyrimidin-derivate
EP0784974A4 (de) Feste dispersion oder zubereitung von xanthinderivaten als feste dispersion
DK0593511T3 (da) Piperidinderivater
MXPA02011417A (es) 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos.
EP1063228A4 (de) Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung
HUT53099A (en) Process for producing new tetrahydrobenzimidazole derivatives and pharmaceutical compositions comprising such compounds
WO2005012220A3 (en) Cycloalkylidene compounds as modulators of estrogen receptor
DE69229257D1 (de) Xanthinderivate zur Behandlung der Demenz
EA200000336A1 (ru) Антагонисты рецептора витронектина
ATE127792T1 (de) 1-arylimidazol-pestizide.
YU45582B (sh) Postopek za pripravo derivatov arilamina
EP0680960A4 (de) Imidazolverbindung.
DE69319900D1 (de) N,n'-disubstituierte amidderivate
DE69626624D1 (de) Medikamente gegen trhombocytopenie
EP0976735A4 (de) Verfahren zur herstellung von piperidincarbonsäureamiden
AU696458B2 (en) Optically active, substituted phenylalkylamine derivatives

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties